Women with an intact uterus treated for HRT must be prescribed both estrogen and progestin due to:

Hormone replacement therapy (HRT) is used to manage menopausal symptoms such as hot flashes, vaginal dryness, and sleep disturbances by replacing declining estrogen levels. In women with an intact uterus, estrogen therapy must be carefully balanced with progestin to protect the endometrial lining. Unopposed estrogen stimulates endometrial proliferation, which increases the risk of abnormal hyperplasia and malignancy. Understanding this balance is essential for safe long-term hormone therapy. Rationale: A. Reduced risk for colon cancer is not the primary reason for adding progestin to hormone therapy. While some studies suggest combined hormone therapy may have minor effects on colorectal cancer risk, this is not the clinical rationale for dual therapy. The key concern in prescribing HRT is endometrial safety, not cancer prevention in the colon. B. Combined hormone therapy does not reduce the risk of venous thromboembolism (VTE). In fact, both estrogen-only and combined therapies can increase thrombotic risk depending on route and patient factors. The addition of progestin is specifically for endometrial protection, not for reducing clotting risk. C. Unopposed estrogen significantly increases the risk of endometrial hyperplasia and endometrial cancer in women with an intact uterus. Therefore, a progestin must be added to counteract estrogen’s proliferative effect on the endometrial lining. This protective mechanism is the primary reason for prescribing combination therapy in hormone replacement regimens. D. While combination therapy may help relieve menopausal vasomotor symptoms such as hot flashes, this is not the reason progestin is required. Hormone replacement therapy is primarily structured to balance estrogen’s effects on the endometrium rather than to enhance symptom relief. Symptom control is a benefit, but not the safety indication for adding progestin.